Who We Are
Hepasonica Arabia is a UAE-based pharmaceutical company committed to advancing ethical, science-driven healthcare solutions across the MENA and GCC regions. As the regional extension of the parent pharmaceutical organization, we bring global pharmaceutical expertise into local focus — combining cutting-edge research, quality-driven manufacturing, and regulatory excellence.
We specialize in delivering high-quality, halal-certified pharmaceutical products, starting with ovine-derived low molecular weight heparins (LMWHs) such as Ovinox™, and aim to broaden our portfolio to include other essential therapies in cardiovascular, surgical, and hematologic care.
Our Mission
To deliver safe, innovative, and ethically developed pharmaceutical products that meet international standards while serving the unique clinical and cultural needs of the region.
Our Vision
To become the region’s most trusted pharmaceutical partner by integrating scientific excellence, responsible innovation, and global quality standards — all rooted in patient-centric care.
What Sets Us Apart
Core Values
- Ethics & Transparency
- Scientific Rigor
- Regional Responsibility
- Quality & Compliance
Our Strengths
- Global pharma alignment (USP/EP/BP/IP)
- Halal-certified and culturally compliant
- Backed by world-class advisory board
- GMP manufacturing & regulatory foresight
Ethics & Transparency
Scientific Rigor
Regional Responsibility
Quality & Compliance
Strengths
Our Strengths
- Global pharma alignment (USP/EP/BP/IP)
- Halal-certified and culturally compliant
- Backed by world-class advisory board
- GMP manufacturing & regulatory foresight
Our Network
As part of the Ronnsi global group, we collaborate with international scientific experts and strategic partners to accelerate the delivery of advanced therapies — supporting healthcare providers with products they can trust.
Our Journey
We are proud of our global heritage and local evolution. Here’s a look at the milestones that shaped who we are today:
Date | Milestone |
Dec 2012 | Suzhou Ronnsi Pharma founded in China |
Jun 2013 | Agreement signed with R-Pharm (Russia) to develop Copaxone |
Aug 2015 | Collaborations established with US Loyola University & Ronzoni Institute (Italy) to characterize ovine enoxaparin |
Jan 2016 | Agreement signed with Indonesia Metiska for ovine enoxaparin |
Jul 2017 | Passed Oncogenrix audit |
Aug 2017 | Achieved ISO9001 certification |
Apr 2019 | Obtained Halal certification for heparin sodium and enoxaparin |
Sep 2019 | Completed Indonesia BPOM audit |
Mar 2025 | Ovinox™ approved in UAE as the world’s first halal-certified LMWH |
2025 | Hepasonica Arabia established in the United Arab Emirates to serve the MENA and GCC markets |